Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells, covering 2025-07-30 to 2025-07-30. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor [Phase 1, Phase 2]